AQST
Aquestive Therapeutics, Inc.
NASDAQ · Healthcare · Drug Manufacturers - Specialty & Generic · US
$3.83
+1.32%Year over year
Reported trailing growth
- Revenue
- +22.6%
- EBITDA
- -29.2%
- EBIT
- -0.3%
- EPS
- +7.1%
- Free cash flow
- +8.1%
- Operating cash flow
- +8.7%
Forward estimates
Based on analyst estimates
- Revenue
- +1.0%
- EBITDA
- +25.3%
- EPS
- +23.0%
Three-year CAGR
- Revenue
- -2.2%
- EBITDA
- —
- EBIT
- —
- Net income
- -89.8%
- EPS
- -49.0%
- Free cash flow
- -47.5%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Jun 1, 2026